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Botulinum neurotoxin A for male lower urinary tract symptoms
Emmanuel Chartier-Kastlera, Ulrich Mehnerta, Pierre Denysb and
Francois Giulianob
Introduction
Botulinum neurotoxin A (BoNT/A), long been used by
neurologists for the treatment of focal spasticity of
striated skeletal muscles, has been introduced into the
field of urology in 1988 for the treatment of Detrusor-
Sphincter-Dyssynergia [1]. In 2000, the first BoNT/A
application in the smooth detrusor muscle in patients
with neurogenic detrusor overactivity was described [2],
followed in 2003 by the first results on the injection of
BoNT/A into the prostate gland for the treatment of
benign prostate hyperplasia (BPH) [3].
BoNT/A is a 150-kDamolecule, consisting of a heavy and
a light chain. The knownmechanism of action on striated
skeletal muscles is the inhibition of acetylcholine release
at motoric axon terminals [4,5]. Thus, it causes a flaccid
muscle paralysis, which is however of limited duration
(months) due to resprouting of the axon terminals.
Therefore, regular reinjection becomes necessary [4].
Basic research on the mechanism of action of BoNT/A in
the human and animal urinary bladder rapidly provided
evidence of additional BoNT/A effects, including modu-
lation of urothelial and suburothelial receptor expression
and neurotransmitter release [6].
Recent research on BoNT/A injections into the prostate
revealed further mechanisms of action of BoNT/A
and reported promising results for the therapy of
lower urinary tract symptoms (LUTS) due to BPH
(LUTS/BPH).
This review summarizes and highlights the most recent
findings in basic and clinical research on the use of
BoNT/A for BPH.
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Purpose of review
Lower urinary tract symptoms (LUTS) related to benign prostatic hyperplasia (BPH)
affects a large number of male patients from 45 years onward, increasing with age.
Routine medical treatment is mainly limited to plant extracts, a-blockers, and 5-a-
reductase inhibitors. Although all types of drug have a proven efficacy, they often do not
sufficiently treat all aspects of LUTS related to BPH. Thus, there is a need for
alternatives. Intraprostatic injections with botulinum neurotoxin type A (BoNT/A) seem
to be a promising alternative. The purpose of this review is to summarize the most recent
findings from basic science and clinical studies in relation to BoNT/A application in
BPH-related LUTS, thereby providing insight into the putative mechanism of action, the
rationale for the use of BoNT/A in BPH-related LUTS, and the clinical outcomes.
Recent findings
There is some evidence that BoNT/A intraprostatic injections affect both, the static and
dynamic component of BPH-related LUTS by reducing the prostate volume and by
downregulation of a-1A-adrenoreceptors. Clinical trials demonstrated an easy and
minimally invasive intraprostatic application of BoNT/A with a favourable safety profile.
Efficacy seems to be good with significant improvements for several months in
symptoms, urinary flow rate and reduction in postvoid residual, prostate volume, and
also prostate-specific antigen in some studies.
Summary
BoNT/A seems to be a promising alternative in the treatment of BPH-related LUTS with
a good tolerance and safety profile. However, the level of evidence is still low and further
randomized controlled studies are mandatory.
Keywords
benign prostatic hyperplasia, botulinum neurotoxin A, international prostate symptom
score, intraprostatic injection, lower urinary tract symptoms
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Basic science and proposed mechanism of
action
BPH-related LUTS are commonly characterized by a
static component related to prostate overgrowth, and by a
dynamic component related to an increase in bladder
neck/prostatic/urethral smooth muscle cells (SMC) con-
tractile tone. Current pharmacological treatment options
target each component separately. Indeed, 5-a-reductase
inhibitors (5-ARI) cause prostate tissue shrinkage,
thereby targeting the static component, while prostatic/
urethral SMC relaxation is achieved by a-1-adrenergic
receptor blockers.
Prostatic SMC tone is mainly controlled by sym-
pathetic innervation while prostate size is under both
sympathetic and parasympathetic innervation influ-
ences [7]. As BoNT/A could act on both sympathe-
tic and parasympathetic innervation [8], it makes
sense to investigate the use of BoNT/A to impact both
static and dynamic components of BPH/LUTS. How-
ever, preclinical studies supporting such effects are
scarce.
Effects of botulinum neurotoxin type A on the static
component of benign prostatic hyperplasia-related
lower urinary tract symptoms
Most of the animal studies have provided evidence that
intraprostatic BoNT/A toxin injections induce prostate
size reduction in animals [9–11,12,13].
Silva et al. [13] performed intraprostatic injections of
saline or 10 units (U) Botox in adult male Wistar rats, and
reported a significant 30% lower prostate weight 1 week
after intraprostatic Botox injections compared to vehicle
injections.
Nishiyama et al. [12] also reported a significant lower
prostate weight of, respectively, 36 and 22% at 1 and
4 weeks after intraprostatic injection of a newly purified
neurotoxin issued fromBoNT/A (when compared to saline
injection).
The main concern with these preclinical data is the fact
that they were conducted in normal rats. To date, the
only published work performed in an experimental
model of BPH in dogs does not report any significant
effect of BoNT/A on prostate weight [14]. Nevertheless,
these results need to be interpreted cautiously since they
were obtained from only two animals in each experimen-
tal group.
Therefore, there is a need for more preclinical data to
better investigate the effects of intraprostatic BoNT/A
on prostate size in an experimental model of BPH.
Mechanisms of action of botulinum neurotoxin type A
on the static component of benign prostatic
hyperplasia-related lower urinary tract symptoms
The best characterized mechanism of action of BoNT/A-
induced reduction of prostate volume is the promotion of
apoptosis that has been described in both humans [15]
and animals [9,10,12,13,14].
Silva et al. [13] reported that apoptosis rate is clearly
enhanced in adult rat prostate 1 week following 10U
intraprostatic Botox injection. Interestingly, this study
showed that parasympathetic denervation may not
participate to this proapoptotic effect while sympathetic
innervation restoration by phenylephrine reduced apop-
tosis rate by 60%. Prostate atrophy [9,11,12,14,16] and
decreased proliferation rate [9] have also been identified
in rat and dog prostates treated with BoNT/A. Indeed,
using a purified botulinum neurotoxin A, Nishiyama et al.
[12] observed histologically a partial atrophy of the
prostate gland 1 week following intraprostatic injection
in rats. Such an atrophy characterized by acini dilation
and epithelial cells flattening was generalized to all parts
of the prostate 4 weeks following injection. However, in
human prostate, no sign of prostate atrophy could be
identified following intraprostatic BoNT/A injection [15].
It is therefore likely that intraprostatic BoNT/A-induced
prostate tissue shrinkage involves the enhancement of
apoptosis rate. However, the possible involvement of
decreased proliferation rate and/or tissue atrophy in the
beneficial effects of intraprostatic BoNT/A still need to
be confirmed in human BPH tissue.
Effects of botulinum neurotoxin type A on the dynamic
component of benign prostatic hyperplasia-related
lower urinary tract symptoms
Lin et al. [11] reported the consequences of intraprostatic
BoNT/A injections on prostatic/urethral SMC tone. In
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Key points
 There is a scientific rationale for the effect and use
of BoNT/A intraprostatic injections in the treat-
ment of BPH-related LUTS.
 BoNT/A intraprostatic injections probably deploys
its effect on BPH-related LUTS by reduction of
prostate volume and number of a-adrenoceptors.
 Reduction in prostate volume seems to be caused
by apoptosis and glandular atrophy (demonstrated
in animals only).
 Application technique is simple and safe and the
clinical results seem promising with significant
reduction in symptoms, urine flow, and postvoid
residual.
 Level of evidence is still low in basic science and
clinical studies, making further research and
randomized controlled trials mandatory.
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dogs, while intraprostatic injection of 100U Botox did not
have any effect, 200U reduced both in-vitro prostate
strips contractile responses to KCl, phenylephrine and
electrostimulation, and in-vivo urethral pressor responses
to i.v. norepinephrine [11]. It is to be noted that these
experiments have been performed in dogs without pros-
tate enlargement and that the effects of intraprostatic
BoNT/A on prostatic/urethral SMC reactivity in an
experimental model of BPH has not been reported
to date.
Mechanisms of action of botulinum neurotoxin type A
on the dynamic component of benign prostatic
hyperplasia-related lower urinary tract symptoms
It has been reported that intraprostatic Botox downregu-
lates the expression of a-1A-adrenoreceptor within rat
prostate [9]. Since an overall nine-fold increase in a-1A-
adrenoreceptor has been observed in BPH compared
with normal prostate [17], and a-1-adrenoreceptors
antagonists are successfully used to relieve prostatic/
urethral obstruction associated with increased SMC
contractile tone in BPH, the downregulation of prostatic
a-1A-adrenoreceptors expression following intraprostatic
BoNT/A injection [9] represents a strong rationale for
using such a treatment for symptomatic BPH. This is
further supported by Lin et al. [11] who demonstrated
that, in dogs, intraprostatic 200U Botox injection
reduced the contractile activity of the prostate when
observed 1 month after injection. In this study, it was
suggested that two mechanisms could be responsible for
such an effect: an impaired release of norepinephrine
from adrenergic nerves and an impaired contractile
machinery of stromal SMC. Prostate SMC vacuolization
was observed and constitute a plausible explanation for
the in-vitro decreased contractile response of prostate
tissue to KCl. However, it is still needed to determine
whether this effect lasts over time or constitutes an
irreversible cellular toxic effect. Interestingly, it has also
been demonstrated that the cleavage of SNAP-25 (a
component of the SNARE complex) by BoNT/A light
chain increased outwards potassium currents channels in
oesophageal SMC [18]. This effect would tend to hyper-
polarize the membrane and thereby decrease smooth
muscle tone, since potassium channels constitute an
important component of SMC contractile machinery.
Studies are however needed to identify such an effect
in prostate SMC.
Findings from clinical studies: from technique
to indications
In patients, intraprostatic BoNT/A injections exert
beneficial effects on BPH-related bladder dysfunction
that are linked to prostatic urethral obstruction relief
[reduction of the International Prostate Symptom Score
(IPSS) voiding symptoms component], but also to blad-
der dysfunction by itself (reduction of IPSS storage
symptoms component). Indeed, the decrease in storage
symptoms component of IPSS accounts for 20–55% of
total IPSS reduction following intraprostatic BoNT/A
injection [19,20].
Three formulations of BoNT/A are currently commer-
cially available, namely Botox (Allergan, Irvine, Califor-
nia, USA), Dysport (Ipsen, Paris, France), and Xeomin
(Merz, Frankfurt am Main, Germany). They mainly
differ in their envelope proteins covering the BoNT/A
molecule and in the application dosage. None of them is
yet licensed for the treatment of LUTS or BPH. Thus,
application of BoNT/A for LUTS/BPH remains off-
label use.
Technique and dosage
In most studies a transperineal injection route with
transrectal ultrasound guidance has been described
(Table 1), but transrectal and transurethral application
routes have been also used [21–26,27]. Usually a 20–
22G needle is used to perform one to two injections per
lobe either without or under local or light general anaes-
thesia. A total of 200U Botox in different dilutions are
most frequently used, although there is no rationale for
this, as dose finding studies are still missing.
Efficacy
The most frequently used outcome parameters to evalu-
ate the efficacy of BoNT/A intraprostatic injections on
BPH-related LUTS are the IPSS or the American Uro-
logical Association Symptom Index (AUA-SI) (Table 2),
Quality of Life Index (QoL-I), maximum urinary flow
rate (MUFR), prostate volume, postvoid residual volume
(PVRV) and serum levels of prostate-specific antigen
(PSA) (Table 2).
The first and still only randomized, placebo-controlled
trial on the efficacy of BoNT/A for BPH-related LUTS
was published by Maria et al. in 2003 [3]. This trial
investigated 30 50–80-year-old patients with moderate-
to-severe BPH symptoms (Table 3). Patients were either
injected with 200U Botox or saline. AUA-SI, MUFR,
prostate volume, serum PSA level, and PVRV were
evaluated at baseline, 1, 2, 6, and 12 months after injec-
tion with unblinding after 2 months [3]. BoNT/A injec-
tions demonstrated significant improvements in all study
parameters at 1 and 2 months post-treatment (65%
improvement in AUA-SI and 51% decrease of serum
PSA) (Table 2). In contrast, placebo did not show any
differences to baseline, which is remarkable as placebo
usually shows some effect that can reach up to 30% in
randomized controlled trials using a-blockers for BPH
[28,29]. Follow-up at 6 and 12 months demonstrated
persistent efficacy up to 12 months in all parameters
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18 Benign prostatic hyperplasia
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(Table 2). This study represents the starting point of
human studies.
Similar results in a similar study population were reported
by Brisinda et al. in 2009 [24] (Table 3). In a prospective
open-label study, 77 patients received 200U Botox. At
1 and 2 months AUA-SI, MUFR, prostate volume, serum
PSA level, and PVRV were significantly improved
(Table 2). Retreatments with 200U were possible, if
patients reported no improvements. After the first treat-
ment 71% of patients reported significant improvements.
The results remained stable up to 30 months [24]
(Table 2). However, 43 reinjections were performed
during that time.
In 2006, Chuang et al. [22] reported on the effect of a
prostate size-related BoNT/A dosing (100U for <30ml
and 200U for >30ml) in 41 BPH-patients who failed
treatment with 5-ARI and/or a-blocker (Tables 1 and 3).
Significant improvements were observed in IPSS, QoL-I,
MUFR, and prostate volume up to 12 months with
slightly greater changes of parameters in the 200U group
[22] (Table 2). This later observation might be due to the
fact that 200U were used in larger prostates, which
provides a larger impact area and a larger margin for
improvements. PVRV showed significant improvements
only at 3 months in the 100U group and at 1, 2, and
3 months in the 200U group [22].
The first results using Dysport on LUTS/BPH were
recently reported by Nikoobakht et al. [27] in a pro-
spective open-label study. A population of 72 males was
included using similar inclusion criteria as Maria et al.
(Table 3). Follow up was 12 months with intermediate
evaluation at 1 and 6 months. IPSS, Qol-I, PVRV, and
MUFR were evaluated at each follow-up visit. Serum
PSA, prostate volume, urine analysis, and urine culture
were evaluated at 6 months only [27]. All parameters
significantly improved from 1 up to 12 months in the
whole study population with a magnitude of effect that is
comparable to the one observed by Maria et al. (Table 2).
Like Chuang et al. [22], Nikoobakht et al. [27] treated
different prostate sizes with different dosages of BoNT/A
(Table 1). Subgroup analysis showed again differences in
the outcome analysis in means that BoNT/A was more
efficient in patients with larger prostates regarding the
reduction in prostate volume, PSA, and PVRV and the
increase in MUFR (Table 2) [22,27].
Special indications
Several studies already investigated the use of BoNT/A
for BPH-related LUTS in special indications, like especi-
ally small or large prostates, poor surgical candidates, and
as add-on treatment to a-blocker and 5-ARI. The find-
ings are summarized below.
Small prostates
In a small population (n¼ 16), Chuang et al. [15] reported
the efficacy of 100U Botox as a second-line treatment
followinga-blocker therapy in patients with small prostate
volumes (<30ml) and aMUFR less than 12ml/s (Table 3).
IPSS, MUFR, prostate volume, and QoL-I were signifi-
cantly improved from 1 up to 10 months (Table 2). Mean
PVRVwasmarkedly reducedbut standard deviationswere
probably too large to reveal any significance.
Poor surgical candidates for benign prostatic hyperplasia
surgery
Kuo [21] treated 10 patients with 200U Botox who had
severe obstruction but were poor candidates for surgery
due to co-morbidities (Table 3). Results were rated
excellent, if spontaneous voiding occurred in patients
with urinary retention or if patients had improvements in
voiding pressure, MUFR, and PVRV of more than 25%
from baseline values. At 6 months, eight of 10 patients
had excellent results and two patients showed improve-
ment. Follow-up at 3 and 6 months demonstrated sig-
nificant improvements in MURF, PVRV, and prostate
volume (Table 2).
In a similar population of 21 males (poor surgical candi-
dates with urinary retention and indwelling catheters),
Silva et al. [23] reported 2008 about the short-term results
of intraprostatic injections of 200U Botox. At 3 months
postinjection, 17 of 21 patients were able to voluntarily
empty their bladder with a MUFR of 10.3ml/s and mean
PVRV less than 100ml (Table 2). Prostate volume
decreased significantly from 1 up to 6 months [23].
In 2009, Silva et al. [26] reported on the long-term results of
a small subgroup (n¼ 11) of their initial evaluation [23].
Follow-up was 18 months, and although IPSS, PVRV,
prostate volume, QoL-I, and serum PSA seemed to slowly
increase after 6 months, prostate volume remained still
significantly below baseline values and patients remained
onvoluntary voidingup to 18months [26] (Table2).A total
of 200U BoNT/A seem to be a valuable alternative treat-
ment for patients who are not suitable for surgical because
of poor general condition. Especially the fact that indwel-
ling catheters could be omitted after the treatment inmost
of the patients is of great value for the patient.
Add-on treatment in patients with large prostates
Park et al. [20] investigated in 52 patients with LUTS/
BPH the effect of BoNT/A alone and in combination
with a-blocker for 4 weeks. Both groups showed signifi-
cant improvements in IPSS and prostate volume after
1 month with sustained effects up to 6 months in those
patients who participated in the follow-up (Table 2).
MUFR, PVRV, and QoL-I were not improved at any
follow-up. The only difference in both groups was
demonstrated for IPSS-5 (weak stream) in favour of
Botulinum neurotoxin A and LUTS/BPH Chartier-Kastler et al. 19
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the BoNT/A and a-blocker group, which was interpreted
as relative reinforcement of the adrenergic influence by
the anticholinergic effect of BoNT/A [20].
Kuo and Liu [25] investigated the effect of BoNT/A on
BPH-related LUTS in patients with ongoing but not
sufficient treatment with a-blockers and 5-ARI combi-
nation therapy since more than 12 months (Table 3).
Sixty patients were either assigned to receive 200U add-
on intraprostatic Botox injection or continued medical
therapy (control group) [25]. Additional injections were
allowed after 2 months with increasing doses up to 600U,
if initial treatment results were not satisfactorily [25].
Although BoNT/A treatment could significantly reduce
IPSS, Qol-I, and prostate volume and increase MUFR at
6 months, no significant differences versus the control
group were observed at 12 months regarding prostate
volume, IPSS, QoL-I, MUFR, and PVRV. The only
significant difference was observed regarding QoL-I at
6 and 12 months, showing a difference of small amplitude
in favour of BoNT/A treatment [25]. In regard to both,
the study by Park et al. [20] and Kuo and Liu [25], add-on
treatment with BoNT/A to a-blocker and/or 5-ARI treat-
ment seems not to result in additional benefits. However,
study design, patients number and power of both studies
seem not appropriate to finally conclude on an add-on
effect of BoNT/A. Future trials should probably include a
run-in period and try to determine if previous medical
treatment might influence responding rate.
Adverse events
Only very few and generally mild and self-limited adverse
events were reported in some studies (Table 4). Adverse
events that occurred were gross haematuria, urinary reten-
tionandacuteprostatitis [15,25,27].Insomestudiespostop
indwellingcatheterforupto4weekswereappliedroutinely
[23,26] (Table 4). Whether this is generally necessary
remains questionable and requires further investigation.
Although various treatment strategies for BPH may
impact sexual dysfunction (ejaculatory and erectile dis-
orders) [30], only one yet unpublished clinical trial has
examined the effects of intraprostatic BoNT/A on sexual
function and reported a significant improvement of eja-
culatory function without any change in erectile function
[31]. Thus, further studies are needed to investigate the
effects of intraprostatic BoNT/A on bladder function and
to validate its safety on sexual function.
Onset and duration of effect
In summary of the above-mentioned 10 clinical studies
[3,15,20–26,27], mean onset of action seems to be around
3.5 weeks (range 1–6 weeks) after injection. The mean
duration seems to be 11.9 months (range 3–30 months).
However, none of those studies was designed to evaluate
the exact onset and duration of effect on LUTS after
intraprostatic BoNT/A injection. In most studies onset
and duration was dependent on the follow-up scheme.
Some studies evenperformedearly reinjections in patients
with insufficient outcome after first injection [24,25],
thereby influencing the study outcome and analysis of
effect duration. Thus, studies investigating the exact start
and duration of effect are lacking. This is important to be
able to estimate cost-effectiveness. In relation to this, dose
finding studies, investigations on repeated injections, and
studies specifically investigating the impact of the treat-
ment on the QoL using adequate QoL-questionnaires are
also missing.
Ongoing studies
There are currently three active but not yet recruiting
phase II studies registered at ClinicalTrials.gov investi-
gating efficacy and/or safety of BoNT/A intraprostatic
injections for the treatment of BPH-related LUTS. One
is a randomized dose comparison study and two are
randomized placebo-controlled trials. Interestingly, in
one study (NCT00284518), the injection route of
BoNT/A has been changed from transperineal to trans-
rectal, showing that there is still an ongoing discussion
about the best route of application. There is also a phase
II randomized active control study investigating intrapro-
static BoNT/A injections for chronic prostatitis and/or
20 Benign prostatic hyperplasia
Table 4 Adverse events in different studies on intraprostatic BoNT/A injections for benign prostatic hyperplasia-related lower urinary
tract symptoms
Study Adverse events Catheterization after injection
Maria et al. [3] None n/a
Chuang et al. [15] Transient and mild dysuria and haematuria in
three patients during the first 24 h posttreatment
For 1 week in one patient with indwelling catheter
Kuo [21] None Three patients needed CISC for 2 weeks postop
Chuang et al. [22] None Only in patients with indwelling catheter
Park et al. [20] None n/a
Silva et al. [23] None Foley catheter for 1 month in all patients
Brisinda et al. 24] None n/a
Kuo and Liu [25] In totally 50 injections, transient acute urinary retention
occurred after 3 (6%), gross haematuria after 7 (14%)
and acute prostatitis after 1 (2%) injection
n/a
Silva et al. [26] None Foley catheter for 1 month in all patients
Nikoobakht et al. [27] Self-limited gross haematuria in three patients (4.2%) n/a
BPH, benign prostatic hyperplasia; CISC, clean intermittent self-catheterization; LUTS, lower urinary tract symptoms.
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chronic pelvic pain syndrome. Last but not least, there is
a randomized, placebo-controlled phase II study cur-
rently recruiting that investigates the influence of intra-
prostatic BoNT/A injections on semen quality.
Conclusion
There is a rationale for the use of intraprostatic BoNT/A to
impact both static and dynamic components of BPH/
LUTS. Further preclinical data are needed to better
investigate these effects and the exact mechanisms of
action of BoNT/A within the prostate. Clinical studies
show very promising results with significant symptom
relief in the majority of treated patients. The application
technique is easily feasible and seems to have a low-risk
profile with only rare ormild adverse events. However, the
level of evidence is still very low and in viewof that BoNT/
A intraprostatic injections are still off-label use, no general
recommendation for the BPH population can be given.
There is still very little information on exact onset and
duration of effect, on the dose–effect relation, on changes
in QoL, on comparison to other or placebo treatment, and
on adverse events on sexual function and semen quality.
The results of ongoing controlled trials have to be awaited
to increase the level of recommendation.
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